GeneOhm
Sciences has developed a proprietary platform for multiplexed
molecular diagnostics for rapidly identifying and controlling
infection and it supports our initiatives to transform patient care,"
commented Dr. Peter Klemm, President and CEO of GeneOhm Sciences. These are the first molecular diagnostic
products to be cleared as meeting the specifications required to
replace culture for microorganism detection.999%).

antibiotic staphylococcus

GeneOhm Sciences Closes Follow-on Series C Funding from Partners Healthcare

Further preclinical in vitro testing has demonstrated Microbisol's
immediate kill of viruses, including HIV, rotavirus, feline calicivirus , Avian
Flu and Influenza A in aqueous suspension. These
statements are based on management's current expectations and are subject to
risks and uncertainties that may cause actual results to differ materially
from these expectations.

vancomycin mycotic

Its product
portfolio includes two assays cleared by FDA and Health Canada for
rapid detection of Group B Streptococcus (IDI-Strep B(TM)) and
Methicillin -Resistant Staphylococcus aureus (IDI-MRSA(TM)) directly
from clinical specimens. According to the CDC, approximately
90,000 hospital patients die each year as a result of these hospital-acquired
infections, and the cost of these infections to the U. The CDC states that improving hand hygiene
is one of the most effective means of preventing the spread of infection
within health care settings .

GMP Anti-Infective Solutions is developing Microbisol for health care uses
in collaboration with The Procter + Gamble Company (P+G) under a license
agreement from P+G which provides GMP exclusive worldwide rights to market
medical grade formulations of the technology to all medical settings (human
and veterinary), commercial and industrial customers, including government
agencies, food service providers and schools and use in addressing public
health needs.

vrsa overuse

News and World Report annual national hospital "Honor Roll". FORT LAUDERDALE, Fla.
In preliminary in vitro anti-fungal testing, Microbisol also achieved near
complete and persistent kill of several strains of the fungus , Candida
albicans. To learn more
about GMP Companies, visit http://www.

antibiotic germs

Preclinical in vitro experiments show that the
application of Microbisol almost completely (99.S. GMP Companies assumes no obligation to update
the statements in this press release or in any other disclosures that include
forward -looking statements, which speak as of their respective dates.

improper vrsa

mycotic pharmacological

Partners' founding members, Brigham and Women's Hospital (BWH) and
Massachusetts General Hospital (MGH), have consistently been named to
the U.

aureus antimicrobial

"We believe that GeneOhm's rapid, molecular diagnostic products
can transform the practice and outcome of infection detection and
control in a way that will make important improvements in
health-economics and patient care.

GeneOhm Sciences is a molecular diagnostic company with locations
in San Diego, CA and Quebec City, Quebec, Canada.

GMP Companies Inc. Announces Results of Preliminary In Vitro Testing of Novel Topical Anti-Infective Technology

GMP has
commercialized other health care products such as the Life Sync(R) wireless
ECG system which is being marketed throughout the United States.

enterococci resistance

Caution Concerning Forward-Looking Statements
This press release includes certain forward-looking statements.

pharmacological repeated

Microbisol is being developed for potential use as an antimicrobial hand
wash solution, a surgical hand scrub and a patient pre-operative skin
preparation product. "We are optimistic that this technology may have important potential to
help reduce the risk of hospital-acquired infections and prevent the spread of
bacteria and other infectious agents in health care settings, where they are
responsible for high costs in lives and dollars.

About GMP Companies, Inc.

prudent microorganisms

These
diagnostic products will serve unmet needs in a wide range of
diseases, including infectious diseases, inherited diseases and
oncology.

"
GMP's anti-infective product is being tested for potential broad-spectrum
antibacterial activity in both human and veterinary applications.
Additional preclinical and clinical (human) testing will be required to
assess the significance of the preliminary in vitro efficacy data and to
assess the safety of Microbisol. Approval from the Food + Drug Administration
(FDA) for these asepsis applications is required prior to commercialization.
contract an infection while hospitalized.

resistant microorganisms

D. It is expected that this technology, if approved by the FDA,
will be broadly commercialized for use in health care settings, including
hospitals, physician offices, outpatient medical facilities, home health care
and veterinary medical facilities.
About GMP Companies, Inc.

antibiotics vancomycin

It joins a
syndicate of investors providing funding to accelerate the
commercialization of GeneOhm's portfolio of molecular diagnostic
products for applications in a number of areas, including rapid
detection of bacterial infection and antimicrobial resistance.

About GeneOhm Sciences, Inc. Preliminary in vitro testing has also indicated
Microbisol's potential to kill several other bacteria, including E.

staphylococcus enterococci

"We are excited to welcome Partners HealthCare as an investor. health care system is
estimated at $5 billion annually . P+G has retained the rights to develop and
market a retail version of the technology.

microorganisms antimicrobial

Partners HealthCare is an integrated healthcare system of
advanced tertiary and community-based medical centers . The solution is also
effective at persistently (up to 14 hours) killing methicillin-resistant
Staphylococcus aureus (MRSA) to near complete levels (99.S.

bacteria mrsa

Business Editors/Health/Medical Writers
BIOWIRE2K

SAN DIEGO----GeneOhm Sciences, an
emerging leader in molecular diagnostics, announced that the company
closed follow-on Series C funding with Partners HealthCare System,
Inc. and its subsidiaries
develop and commercialize biotechnology and medical technology products.com .

pharmacological vancomycin

Their commitment validates the importance of our products.9999%) and persistently (up to
14 hours) kills vancomycin -resistant enterococci (VRE).
The CDC estimates that each year nearly two million patients in the U.

pharmacological untold

The Company's preliminary in vitro
experiments also show persistent killing of the viruses HIV, rotavirus, and
Avian Flu on artificial skin for at least 4 hours.

overuse improper

Their products provide significant
advantages over standard, culture-based methods in time-to-result,
performance and cost," said Jean Moses, Director of Corporate
Development, Partners HealthCare., a biotechnology and medical technology health care company, announced
today that its GMP Anti-Infective Solutions, Inc.

bacterial resistance

S., Senior Vice President for GMP Companies,
Inc. Such risks and uncertainties include, but are not
limited to, the ability to obtain FDA approval of products embodying the
Company's anti-infective technology , the results of additional preclinical and
clinical testing of such products, the efficacy and safety of such products,
and the ability to successfully develop and commercialize such products if
ultimately approved by the FDA.

staphylococcus prudent

Future products include
assays to detect vancomycin resistance and Methicillin sensitive
staphylococcus aureus., GMP Companies,
Inc. According to the Centers for Disease Control and Prevention (CDC),
Candida albicans is a major cause of nosocomial infections from indwelling
intravascular catheters in health care institutions.gmpcompanies.

resistance bacteriology

GeneOhm's rich product pipeline is based on the
company's broad portfolio of molecular-based technology for processing
and detecting nucleic acids from a variety of specimens.

vancomycin mycotic

coli and
Serratia marscesens for up to 14 hours. Preliminary
tests in aqueous suspension suggest that this formulation can kill 46
additional bacteria strains , including several different strains of
Enterococcus, Staphylococcus aureus, Streptococcus agalactiae and Escheria
coli.

resistance staphylococcus

The system includes leaders in biomedical research and major teaching
affiliates of the Harvard Medical School. subsidiary completed
preliminary in vitro testing of Microbisol(TM ), a new, non-alcohol based
topical agent designed to prevent the spread of serious infections in
hospitals, medical facilities and a broad array of health care settings. VRE and MRSA
are responsible for some of the most serious, and sometimes lethal, hospital-
acquired infections.
"We are very pleased with the results of our preliminary in vitro testing
thus far," said George Titus, Ph .

germs staphylococcus

-- GMP Companies, Inc. These
technologies are typically licensed or acquired from academic medical centers,
individual inventors, research institutions and partner companies.

antimicrobial mycotic

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)